Fastonib-ER
Tofacitinib 11mg Extended Release Tablet is a Janus kinase (JAK) inhibitor that is used to treat certain autoimmune diseases. Unlike the standard immediate-release formulation, the extended-release version allows for once-daily dosing, providing convenience to patients. It works by modulating the immune system, reducing inflammation in conditions like rheumatoid arthritis and ulcerative colitis.
- Recommended Usage
Indications
Tofacitinib 11mg Extended Release is indicated for the treatment of:
- Rheumatoid Arthritis (RA): For moderate to severe active rheumatoid arthritis in adults who have had an inadequate response to or intolerance to methotrexate or other conventional disease-modifying antirheumatic drugs (DMARDs).
- Psoriatic Arthritis (PsA): For adults with active psoriatic arthritis.
- Ulcerative Colitis (UC): For the treatment of moderate to severe active ulcerative colitis in adults, particularly in those who have had an inadequate response to conventional therapy.
Dosage and Administration
Rheumatoid Arthritis:
- Starting dose: 11 mg once daily (extended-release tablet).
- If needed, dose may be adjusted to 5 mg once daily or as directed by the healthcare provider.
Psoriatic Arthritis:
- Starting dose: 11 mg once daily (extended-release tablet).
- Maintenance doses can be 5 mg to 10 mg once daily.
Ulcerative Colitis:
- Starting dose: 10 mg once daily for 8 weeks, followed by 5 mg once daily or as recommended by the healthcare provider.
Tofacitinib 11mg Extended Release should be taken once daily, with or without food, and must be swallowed whole. Do not crush or chew the tablet.
Precautions
Infection Risk: Increased risk of serious infections, including tuberculosis, bacterial, viral, and fungal infections. Prior screening for infections is necessary before starting treatment.
Liver Function: Tofacitinib can affect liver enzymes. Regular monitoring of liver function tests is required.
Blood Disorders: May cause low white blood cell counts (leukopenia), low red blood cells (anemia), and low platelets (thrombocytopenia). Blood counts should be monitored regularly.
Cancer Risk: Long-term use can increase the risk of certain cancers. Patients should be regularly monitored for malignancy.
Cardiovascular Health: Can increase cholesterol levels and affect blood pressure. Monitoring is recommended, especially for patients with cardiovascular risk factors.
Vaccination: Live vaccines should be avoided during treatment with tofacitinib. Patients should be up to date on their vaccinations before starting therapy.
Pregnancy and Breastfeeding: Not recommended during pregnancy or breastfeeding. Discuss with your healthcare provider the potential risks and benefits.
Kidney and Heart Conditions: Caution is required in patients with pre-existing kidney or heart conditions. Dose adjustment may be needed.
